X Tao1, K S Hill1, I Gaziova1, S K Sastry2, S Qui3, P Szaniszlo4, S Fennewald4, V A Resto5, L A Elferink6. 1. Department of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States. 2. Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States; Department of Sealy Center for Cancer Biology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States. 3. Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States; Department of Sealy Center for Cancer Biology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States. 4. Department of Otolaryngology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States. 5. Department of Otolaryngology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States; Department of Sealy Center for Cancer Biology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States. 6. Department of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States; Department of Sealy Center for Cancer Biology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States. Electronic address: lisa.elferink@utmb.edu.
Abstract
OBJECTIVES: The hepatocyte growth factor receptor (Met) is frequently overexpressed in Head and Neck Squamous Cell Carcinoma (HNSCC), correlating positively with high-grade tumors and shortened patient survival. As such, Met may represent an important therapeutic target. The purpose of this study was to explore the role of Met signaling for HNSCC growth and locoregional dissemination. MATERIALS AND METHODS: Using a lentiviral system for RNA interference, we knocked down Met in established HNSCC cell lines that express high levels of the endogenous receptor. The effect of Met silencing on in vitro proliferation, cell survival and migration was examined using western analysis, immunohistochemistry and live cell imaging. In vivo tumor growth, dissemination and mouse survival was assessed using an orthotopic tongue mouse model for HNSCC. RESULTS: We show that Met knockdown (1) impaired activation of downstream MAPK signaling; (2) reduced cell viability and anchorage independent growth; (3) abrogated HGF-induced cell motility on laminin; (4) reduced in vivo tumor growth by increased cell apoptosis; (5) caused reduced incidence of tumor dissemination to regional lymph nodes and (6) increased the survival of nude mice with orthotopic xenografts. CONCLUSION: Met signaling is important for HNSCC growth and locoregional dissemination in vivo and that targeting Met may be an important strategy for therapy.
OBJECTIVES: The hepatocyte growth factor receptor (Met) is frequently overexpressed in Head and Neck Squamous Cell Carcinoma (HNSCC), correlating positively with high-grade tumors and shortened patient survival. As such, Met may represent an important therapeutic target. The purpose of this study was to explore the role of Met signaling for HNSCC growth and locoregional dissemination. MATERIALS AND METHODS: Using a lentiviral system for RNA interference, we knocked down Met in established HNSCC cell lines that express high levels of the endogenous receptor. The effect of Met silencing on in vitro proliferation, cell survival and migration was examined using western analysis, immunohistochemistry and live cell imaging. In vivo tumor growth, dissemination and mouse survival was assessed using an orthotopic tongue mouse model for HNSCC. RESULTS: We show that Met knockdown (1) impaired activation of downstream MAPK signaling; (2) reduced cell viability and anchorage independent growth; (3) abrogated HGF-induced cell motility on laminin; (4) reduced in vivo tumor growth by increased cell apoptosis; (5) caused reduced incidence of tumor dissemination to regional lymph nodes and (6) increased the survival of nude mice with orthotopic xenografts. CONCLUSION: Met signaling is important for HNSCC growth and locoregional dissemination in vivo and that targeting Met may be an important strategy for therapy.
Authors: Kauko Saarilahti; Petri Bono; Mikael Kajanti; Leif Bäck; Ilmo Leivo; Timo Joensuu; Jorma Isola; Antti A Mäkitie Journal: J Otolaryngol Head Neck Surg Date: 2010-06
Authors: M F Di Renzo; M Olivero; T Martone; A Maffe; P Maggiora; A D Stefani; G Valente; S Giordano; G Cortesina; P M Comoglio Journal: Oncogene Date: 2000-03-16 Impact factor: 9.867
Authors: Melody A Swartz; Noriho Iida; Edward W Roberts; Sabina Sangaletti; Melissa H Wong; Fiona E Yull; Lisa M Coussens; Yves A DeClerck Journal: Cancer Res Date: 2012-03-13 Impact factor: 12.701
Authors: Lorenzo Lo Muzio; Antonio Farina; Corrado Rubini; Erminia Coccia; Mario Capogreco; Giuseppe Colella; Rosalia Leonardi; Giuseppina Campisi; Francesco Carinci Journal: Tumour Biol Date: 2006-04-11
Authors: Mohammad Obaidul Hoque; Shahnaz Begum; Matthias Sommer; Taekyeol Lee; Barry Trink; Edward Ratovitski; David Sidransky Journal: Cancer Lett Date: 2003-09-10 Impact factor: 8.679
Authors: Tanguy Y Seiwert; Ramasamy Jagadeeswaran; Leonardo Faoro; Varalakshmi Janamanchi; Vidya Nallasura; Mohamed El Dinali; Soheil Yala; Rajani Kanteti; Ezra E W Cohen; Mark W Lingen; Leslie Martin; Soundararajan Krishnaswamy; Andres Klein-Szanto; James G Christensen; Everett E Vokes; Ravi Salgia Journal: Cancer Res Date: 2009-03-24 Impact factor: 12.701
Authors: Ivana Gaziova; Daniel Jackson; Paul J Boor; Dwayne Carter; Zobeida Cruz-Monserrate; Cornelis J Elferink; Aditya D Joshi; Bhupendra Kaphalia; Craig D Logsdon; Karen Pereira de Castro; Lynn Soong; Xinrong Tao; Suimin Qiu; Lisa A Elferink Journal: PLoS One Date: 2016-10-31 Impact factor: 3.240
Authors: Verena Boschert; Nicola Klenk; Alexander Abt; Sudha Janaki Raman; Markus Fischer; Roman C Brands; Axel Seher; Christian Linz; Urs D A Müller-Richter; Thorsten Bischler; Stefan Hartmann Journal: Int J Mol Sci Date: 2020-01-11 Impact factor: 5.923